Savings & Support
Support tailored to your eligible patient’s Retevmo treatment journey*
Enroll your patientsTo enroll your eligible patients in all or any of these support programs*, please call the Lilly Oncology Support Center at 1-866-472-8663, Monday—Friday, 8 AM—10 PM ET.

Retevmo Savings Card
Eligible commercially insured covered patients pay as little as $0 a month.†
Download Savings Card†Offer good for up to 12 months. Patients must have coverage for Retevmo through their commercial drug insurance coverage to pay as little as $0 for a 30-day supply of Retevmo. Offer subject to a monthly cap and a separate annual cap of $25,000. Patient is responsible for any applicable taxes, fees, or amounts exceeding monthly or annual caps. This offer is invalid for Patients without commercial drug insurance or whose prescription claims for Retevmo are eligible to be reimbursed, in whole or in part, by any governmental program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medigap, DoD, VA, TRICARE®/CHAMPUS, or any State Patient or Pharmaceutical Assistance Program. Offer void where prohibited by law and subject to change or discontinue without notice. Subject to additional terms and conditions.
TRICARE® is a registered trademark of the Department of Defense (DoD), DHA.

MyRightDose: A Dose Exchange Program‡
May simplify midcycle dose changes for patients—MyRightDose ships the appropriate dose directly to your patient’s home in as early as 48 hours and at no cost to the patient.
‡Additional terms and conditions apply. See the MyRightDose enrollment form for details.

Retevmo Interim Access Program
The Retevmo Interim Access Program may provide a temporary supply of Retevmo at no cost to insured, eligible patients who have been prescribed Retevmo for the first time and are experiencing a delay in their insurance coverage decision.§
§The Retevmo Interim Access Program (or “Program”) provides a 15-day supply of Retevmo at no charge for eligible, insured patients who are: 1) prescribed Retevmo for the first time after testing positive for a RET alteration, 2) experiencing a minimum 5-business-day delay in insurance coverage determination, 3) prescribed Retevmo for an FDA-approved indication or an indication medically supported by CMS-recognized compendia, and 4) enrolled in the Lilly Oncology Support Center, 5) residents of the United States or Puerto Rico. May not be combined with any other offer. Not available to patients whose insurers have made a final determination to deny the patient coverage for Retevmo. If a denial is received after the initial 5 business days have passed and appeal rights are being pursued, or if there is a persistent coverage delay, the patient, under appropriate circumstances, may be eligible for up to 3 additional 15-day supplies of Retevmo. Product provided through the Program is only available through the Program non-commercial specialty pharmacy. Product is provided free of charge and may not be sold, bartered, or returned for credit. Reimbursement cannot be sought from any third party for product provided under the program. Patients enrolled in Medicare Part D are prohibited from counting any portion of the cost of the product provided under the Program towards true out-of-pocket (“TrOOP”) costs for prescription drug calculations. No purchase contingency or other obligation accompanies program participation. This Program is not health insurance and does not guarantee coverage. Lilly reserves the right to change or end the program at any time. Benefits under the program are not transferable.

Insurance and Coverage Assistance*
Benefits investigation
- Helps eligible enrolled patients understand their coverage options, locate the appropriate specialty pharmacy, and identify their lowest possible out-of-pocket cost
Field reimbursement manager
- Helps patients access prescribed Lilly FDA-approved medicines

Retevmo Digital Starter Kit
The Retevmo Digital Starter Kit provides patients with key information and savings opportunities. Have patients text the following for more information:
RETL to 85099 for Retevmo NSCLC resources
RETT to 85099 for Retevmo thyroid cancer resources
*Retevmo Support programs and offerings are not a guarantee of coverage. Terms and conditions apply for all programs. See enrollment form for details.
Access Resources
Retevmo is available through:

Contracted specialty pharmaciesǁ

Hospital and health system practices

In-office dispensing practices (IODs)
Retevmo is available through contracted specialty pharmacies and can be purchased through authorized distributors.
See a list of specialty pharmaciesǁEligible pharmacies can purchase Retevmo through authorized distribution partners. A list of authorized distributors can be found at lillytrade.com.
Here are some helpful resources to help you and your patients with common access issues

Retevmo access, reimbursement, and distribution
The access and reimbursement landscape can be complex and cumbersome. Information within the guide can help you navigate the complexities of the reimbursement landscape.
Download distribution guide
Coverage authorization appeals letter
If an initial claim or coverage authorization request letter is denied, the payer may require a coverage authorization appeals letter.
Download sample
Letter of medical necessity (LMN)
Many health plans require that an LMN accompany a coverage authorization appeals letter.
Download sample
Treatment plan guide
An easy-to-use resource to help the pharmacy develop electronic order sets that are included in electronic health record systems.
Download treatment plan guide
Enrollment form
Enroll your patients to gain access to the Retevmo support offerings.
Download enrollment formINDICATIONS
Retevmo is a kinase inhibitor indicated for the treatment of:
- adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test
- adult and pediatric patients 12 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy*
- adult and pediatric patients 12 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate)*
- adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options*
*These indications are approved under accelerated approval based on overall response rate (ORR) and duration of response (DoR). Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials.